RESUMEN
BACKGROUND AND OBJECTIVES: Lack of information and myths or inadequate training of health care providers in the guidance and management of contraceptives could negatively affect choice and eventually continuation rates. Our objectives were to evaluate the impact of clinical and theoretical training of health care professionals on insertion and removal of etonogestrel (ENG)-implant regarding this contraceptive, including pre- and post-training knowledge about insertion and removal techniques, clinical characteristics, side effects and outcomes. MATERIAL AND METHODS: We conducted a cross-sectional study in which a questionnaire was sent to health care providers after they received clinical training in the management of ENG-implant. RESULTS: After training, 78.2% of the 139 participants initiated to offer and inserted up to 5 implants/month and 17.6% between 6 to 10/month. None of the interviewees reported having difficulty with insertions after training, and 87.9% reported feeling very confident for removal. CONCLUSION: Theoretical and practical training appeared important to prepare health care professionals, clarify doubts and promote higher rates of use of contraceptive implants in Brazil, contributing to reduce the rates of unintended pregnancies.
Asunto(s)
Anticonceptivos Femeninos , Brasil , Estudios Transversales , Implantes de Medicamentos , Femenino , Personal de Salud , Humanos , EmbarazoRESUMEN
STUDY QUESTION: Is the pain associated with levonorgestrel-releasing intrauterine system (LNG-IUS) insertion reduced by intracervical anesthesia in women without previous vaginal birth? SUMMARY ANSWER: Intracervical anesthesia was not associated with reduced pain in women without previous vaginal birth. WHAT IS KNOWN ALREADY: The pain associated with the insertion of intrauterine contraceptives (IUCs) is a limiting factor for the use of these contraceptives by some women. No prophylactic pharmacological intervention has proven efficacy in relieving pain during or after the insertion of IUCs. However, previous studies included women with previous vaginal delivery, and injectable intracervical anesthesia was not evaluated in any of these studies. STUDY DESIGN, SIZE, DURATION: This was a randomized, open, parallel-group clinical trial that evaluated 100 women without previous vaginal delivery who wished to use the LNG-IUS for the first time. These women were evaluated immediately after LNG-IUS insertion and then 2 h and 6 h later. PARTICIPANTS/MATERIALS, SETTING, METHODS: The 100 women were randomized into two groups: (i) use of a non-steroidal anti-inflammatory drug (NSAID) (ibuprofen, 400 mg) 1 h prior to LNG-IUS insertion; or (ii) 2% lidocaine intracervical injection 5 min prior to LNG-IUS insertion. The women were evaluated immediately after LNG-IUS insertion and then 2 h and 6 h after insertion. Two pain scales were used (the visual analogue scale and the facial pain scale) in addition to assessing the ease of insertion (as rated by the provider) and the level of discomfort during the procedure (as rated by the patient). Multivariate logistic regression was performed to analyze the predictors associated with moderate/severe pain. MAIN RESULTS AND THE ROLE OF CHANCE: The pain and discomfort associated with LNG-IUS insertion, and the ease of insertion of the LNG-IUS did not differ between the groups. Nulliparity was more associated with moderate/severe pain [adjusted odds ratio (OR): 3.1 (95% confidence interval (CI): 1.3-7.80]. Injectable intracervical anesthesia use reduced the risk of moderate/severe pain by 40% [adjusted OR: 0.6 (95% CI: 0.2-1.4)]. The difference between the mean pain score in the intracervical anesthesia group and the NSAID group was <10%; thus, the effect size of the intervention was not significant. LIMITATIONS, REASONS FOR CAUTION: Intracervical anesthesia was compared with an oral medication in this study. Intracervical injection of a saline solution or even a dry needling as the placebo for a double-blind study could be a more adequate control; however, this approach was not a protocol approved by the institutional review board. Considering that the majority of the insertions were easy (>80% in both groups), the results may not be extrapolated to difficult insertions with moderate/severe pain where local anesthesia may have a role. WIDER IMPLICATIONS OF THE FINDINGS: The findings can be generalized to most insertions in nulliparous women or in those without a previous vaginal delivery. There is currently no evidence to recommend the routine use of prophylactic intracervical anesthesia prior to LNG-IUS insertion; there is no evidence that this treatment reduces insertion-related pain. STUDY FUNDING/COMPETING INTERESTS: RAF and CSV give occasional lectures for Bayer Healthcare. This study received funding from the National Institute of Hormones and Women's Health, National Council for Scientific and Technological Development (CNPq). TRIAL REGISTRATION NUMBER: NCT02155166.
Asunto(s)
Anestésicos Locales/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Cuello del Útero/efectos de los fármacos , Dispositivos Intrauterinos Medicados/efectos adversos , Lidocaína/uso terapéutico , Dolor/tratamiento farmacológico , Adulto , Anestésicos Locales/administración & dosificación , Femenino , Humanos , Levonorgestrel/administración & dosificación , Lidocaína/administración & dosificación , Persona de Mediana Edad , Dolor/etiología , Dimensión del Dolor , Resultado del TratamientoRESUMEN
AIMS: To determine the ability of probiotic lactobacilli to improve the treatment of vulvovaginal candidiasis (VVC) using a randomized, double-blind and placebo-controlled trial. METHODS AND RESULTS: Fifty-five women diagnosed with VVC by vaginal discharge positive for Candida spp. (according to culture method) associated with at least one of the symptoms (itching and burning vaginal feeling, dyspareunia and dysuria), were treated with single dose of fluconazole (150 mg) supplemented every morning for the following 4 weeks with two placebo or two probiotic capsules (containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14). At 4 weeks, the probiotic treated group showed significantly less vaginal discharge associated with any of the above mentioned symptoms (10.3%vs 34.6%; P = 0.03) and lower presence of yeast detected by culture (10.3%vs 38.5%; P = 0.014). CONCLUSION: This study has shown that probiotic lactobacilli can increase the effectiveness of an anti-fungal pharmaceutical agent in curing disease. SIGNIFICANCE AND IMPACT OF THE STUDY: This novel finding of probiotic lactobacilli augmenting the cure rate of yeast vaginitis, not only offers an alternative approach to a highly prevalent condition that adversely affects the quality of life of women around the world, but also raises the question of how this combination works.
Asunto(s)
Antifúngicos , Candida/efectos de los fármacos , Candidiasis Vulvovaginal , Fluconazol , Lacticaseibacillus rhamnosus , Limosilactobacillus reuteri , Probióticos , Adolescente , Adulto , Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Candida/clasificación , Candida/aislamiento & purificación , Candidiasis Vulvovaginal/tratamiento farmacológico , Candidiasis Vulvovaginal/microbiología , Candidiasis Vulvovaginal/terapia , Método Doble Ciego , Femenino , Fluconazol/administración & dosificación , Fluconazol/uso terapéutico , Humanos , Persona de Mediana Edad , Probióticos/administración & dosificación , Probióticos/uso terapéutico , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVE: Blood coagulation and fibrinolytic variables were evaluated in 46 Brazilian women treated with either of two monophasic oral contraceptives (OC), containing 30 or 20 microg of ethinyl estradiol, and 75 microg of gestodene. METHODS: The effects on procoagulants, anticoagulants, pro-fibrinolytics and antifibrinolytics and fibrin turnover were evaluated after treatment for six consecutive cycles, the impact of reduction of ethinyl estradiol dosage on these effects being assessed. RESULTS: The OC containing 30 microg of ethinyl estradiol significantly increased the activities of factors VIII and X, whereas the one containing 20 microg of ethinyl estradiol caused no changes in clotting factors. Neither treatment altered fibrinogen levels or factor VII, IX or XII activity. There were no changes in antithrombin levels, but treatment with 30 microg ethinyl estradiol increased protein C levels and treatment with 20 microg decreased total protein S levels. Concerning the fibrinolytic parameters, both OCs increased plasminogen activity, whereas no changes in PAI-1, t-PA, alpha-2-antiplasmin or fibrin degradation products were observed. The reduction in ethinyl estradiol dosage from 30 microg to 20 microg eliminated the effects on factors VIII and X. CONCLUSIONS: The results show that the OC studied did not cause sufficient changes to indicate that there may be a correlation between these laboratory alterations and clinical results. The lack of reports concerning the hemostatic effects of OCs on Brazilian women hinders comparison of the present data with those obtained for other ethnic groups, at different geographical locations, and emphasizes the importance of such a study for future epidemiological investigation of the prothrombotic effects of OCs in Brazilian women.
Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Anticonceptivos Orales Combinados/farmacología , Etinilestradiol/farmacología , Norpregnenos/farmacología , Adulto , Factores de Coagulación Sanguínea/metabolismo , Brasil , Anticonceptivos Orales Combinados/administración & dosificación , Anticonceptivos Orales Combinados/efectos adversos , Relación Dosis-Respuesta a Droga , Congéneres del Estradiol/farmacología , Etinilestradiol/administración & dosificación , Etinilestradiol/efectos adversos , Femenino , Fibrinólisis/efectos de los fármacos , Humanos , Persona de Mediana Edad , Norpregnenos/administración & dosificación , Norpregnenos/efectos adversos , Congéneres de la Progesterona/farmacología , Estadísticas no ParamétricasRESUMEN
We compared the effects of two third-generation progestogens, desogestrel (DSG) and gestodene (GSD), on coagulation and fibrinolysis in Brazilian users of oral contraceptives (OCs). Forty-six women were evaluated before treatment and after six cycles of treatment. The coagulation, anticoagulant, and fibrinolytic systems were investigated. During the use of the DSG-containing OC, the activity of factors VII, VIII, IX, X, and XII increased significantly whereas the GSD-containing OC caused no changes in coagulation parameters. Concerning the anticoagulant pathways, the DSG-containing OC increased protein C levels and decreased total protein S levels, and the GSD-containing OC only decreased total protein S. Both OCs increased plasminogen activity, although the DSG-containing OC increased fibrin degradation products levels and decreased the tissue plasminogen activator antigen. In conclusion, we have found that in Brazilian women the effects of DSG and GSD on hemostatic parameters are different and, therefore, third-generation progestogens may not contribute equally to the thrombotic risk.
Asunto(s)
Trastornos de las Proteínas de Coagulación/prevención & control , Anticonceptivos Sintéticos Orales/farmacología , Desogestrel/farmacología , Hemostasis/efectos de los fármacos , Norpregnenos/farmacología , Congéneres de la Progesterona/farmacología , Adulto , Coagulación Sanguínea/efectos de los fármacos , Brasil/epidemiología , Trastornos de las Proteínas de Coagulación/sangre , Trastornos de las Proteínas de Coagulación/inducido químicamente , Trastornos de las Proteínas de Coagulación/epidemiología , Anticonceptivos Orales/efectos adversos , Anticonceptivos Sintéticos Orales/administración & dosificación , Desogestrel/administración & dosificación , Etnicidad , Femenino , Fibrinólisis/efectos de los fármacos , Humanos , Norpregnenos/administración & dosificación , Congéneres de la Progesterona/administración & dosificaciónRESUMEN
Many literature studies have shown that long-term use of oral contraceptives (OC) is associated with lack of protection of the epithelium of the uterine cervix. Forty-five patients, from 18 to 35 years old, users of two contraceptive formulations, of different estrogenic concentration, took part in this study as volunteers to evaluate the predisposition of the cervix to pathologies. The results found before OC use were 11% of Chlamydia trachomatis infection and 13% of HPV infection. These pathologies were correctly treated and after 5 months of OC use we found total remission of Chlamydia trachomatis infection and 4% of persistent HPV infection. These data lead us to conclude that the OC studied here interfered very little with the presented pathologic results. The risk factors that we considered relevant were: 1) age group (the patients that presented HPV and C. trachomatis infections were young university students); 2) lifestyle (most patients certified that they did not combine the use of barrier contraceptives with the use of OC); 3) multiple sexual partners; 4) low socioeconomic condition.
Asunto(s)
Cuello del Útero/efectos de los fármacos , Anticonceptivos Orales Combinados/farmacología , Anticonceptivos Hormonales Orales/farmacología , Adulto , Factores de Edad , Cuello del Útero/microbiología , Cuello del Útero/patología , Cuello del Útero/virología , Infecciones por Chlamydia/tratamiento farmacológico , Infecciones por Chlamydia/epidemiología , Infecciones por Chlamydia/microbiología , Infecciones por Chlamydia/patología , Chlamydia trachomatis/aislamiento & purificación , Condones/estadística & datos numéricos , Anticonceptivos Orales Combinados/efectos adversos , Anticonceptivos Hormonales Orales/efectos adversos , Susceptibilidad a Enfermedades , Células Epiteliales/efectos de los fármacos , Células Epiteliales/microbiología , Células Epiteliales/patología , Células Epiteliales/virología , Etinilestradiol/efectos adversos , Etinilestradiol/farmacología , Femenino , Humanos , Estilo de Vida , Norpregnenos/efectos adversos , Norpregnenos/farmacología , Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/tratamiento farmacológico , Infecciones por Papillomavirus/epidemiología , Infecciones por Papillomavirus/virología , Factores de Riesgo , Conducta Sexual/estadística & datos numéricos , Parejas Sexuales , Factores Socioeconómicos , Infecciones Tumorales por Virus/tratamiento farmacológico , Infecciones Tumorales por Virus/epidemiología , Infecciones Tumorales por Virus/virología , Neoplasias del Cuello Uterino/epidemiología , Cervicitis Uterina/tratamiento farmacológico , Cervicitis Uterina/epidemiología , Cervicitis Uterina/microbiología , Cervicitis Uterina/patología , Cervicitis Uterina/virología , Displasia del Cuello del Útero/epidemiologíaRESUMEN
Vaginal candidiasis continues to be a common cause of vaginal discharge, pruritus and other local complaints in women worldwide. Although numerous antimycotic agents are available for the treatment of yeast vaginitis there is little comparative data on the in vitro activity of these drugs. The objectives of this study were to isolate and identify the Candida species in the vagina and anus of patients treated in a gynaecology clinic, as well as determine the susceptibility to azolic compounds measured by the E-test method. Vaginal and rectal swabs were collected from 80 adult non-pregnant patients, seen at a gynaecological clinic, aged 18-59 years, with sexual activity, with and without vaginitis. The swabs were processed by methods routinely used for the detection of pathogenic yeasts. The susceptibility of the isolates to fluconazole, ketoconazole and itraconazole, was measured by the agar diffusion method (E-test), using RPM1 1,640 medium with 2% glucose and phosphate buffer. Candida species (33) strains were isolated from 17 patients at similar proportions from both anatomical sites, and 12 patients harboured 24 strains of C. albicans in the vaginal and rectal tracts. Twenty one percent of the strains of C. albicans were resistant to ketoconazole, 54% were resistant to itraconazole and 0% were resistant to fluconazole. The sensitivity of strains isolated from the two sites were similar, indicating that these are strains of the same phenotype.
Asunto(s)
Antifúngicos/farmacología , Candida/efectos de los fármacos , Candidiasis Vulvovaginal/microbiología , Vagina/microbiología , Adolescente , Adulto , Canal Anal/microbiología , Candida/clasificación , Candida/aislamiento & purificación , Farmacorresistencia Microbiana , Femenino , Humanos , Pruebas de Sensibilidad Microbiana/métodos , Persona de Mediana EdadRESUMEN
A tarefa de programar em saude tambem implica em estar atento ao processo de execuçäo e avaliaçäo das açöes de saude. Nessa orientaçäo foi proposto um serviço de atençäo primaria em ginecologia na Unidade de Saude de Vila Tiberio do Centro de Saude Escola de Ribeiräo Preto, no ano de 1985. Este estudo revelou que 36,5% do total de 148 mulheres atendidas possuiam entre 15 e 25 anos de idade; as cervicopatias e doenças sexualmente transmitidas foram os diagnosticos mais frequentes (16,4%). Encontraram-se taxas de alta e abandono de 48,6% e 33,8%, respectivamente, enquanto 17,6% das pacientes continuaram em seguimento. Receberam encaminhamento a outro nível de assistencia 28,4% do total delas, ressaltando-se que em 40,5% deles o motivo foi a falta de eletrocauterio nessa Unidade de Saude